Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium 3

2494 - Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)


10 Oct 2016


Presidential Symposium 3


Karim Fizazi


Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435


K. Fizazi1, S.J. Hotte2, F. Saad3, B. Alekseev4, V.B. Matveev5, A. Flechon6, G. Gravis7, F. Joly8, K.N. Chi9, Z. Malik10, P. Stewart11, C. Jacobs12, T.M. Beer13

Author affiliations

  • 1 Department Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 2 Oncology, Juravinski Cancer Centre, L8V 5C2 - Hamilton/CA
  • 3 Urology, CRCUM-Universite de Montreal, Montreal/CA
  • 4 Urology/oncology, N. N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 5 Research, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 6 Medical Oncology, Centre Léon Bérard, Lyon/FR
  • 7 Medical Oncology, Institute Paoli Calmettes, 13009 - Marseille/FR
  • 8 Medical Oncology, Centre Francois Baclesse, 14000 - Caen/FR
  • 9 Medical Oncology, BC Cancer Agency, Vancouver General Hospital University of British Columbia, Vancouver/CA
  • 10 Clinical Oncology, Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral/GB
  • 11 Clinical Development, OncoGenex Pharmaceuticals, Inc., 98011 - Bothell/US
  • 12 Clinical Research, OncoGenex Pharmaceuticals, Inc., 98011 - Bothell/US
  • 13 Knight Cancer Institute, Oregon Health Science University, 97239 - Portland/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2494


Treatment failure is the major barrier to extending survival in patients (pts) with advanced cancer. Clusterin (CLU) is a cytoprotective protein upregulated by chemotherapy in cancer cells. Custirsen (C) inhibits CLU production in vivo. This international phase 3 study (AFFINITY; Clinicaltrials.gov NCT01578655) evaluated C in combination with cabazitaxel/prednisone (Cbz/P) in pts with mCRPC. Co-primary objectives were to evaluate overall survival (OS) in pts receiving Cbz/P/C compared to pts receiving Cbz/P alone for all randomized (ITT) pts and a poor prognosis subgroup.


Pts with progressive disease after docetaxel, adequate organ function, and Karnofsky score ≥70% were randomized to Cbz/P/C or Cbz/P. Treatment consisted of 21-day cycles of 25 mg/m2 IV Cbz on day 1 with 10 mg oral P daily with or without 640 mg IV C on days 1, 8, and 15 (plus 3 prior loading doses) until disease progression, unacceptable toxicity, or 10 cycles. Overall type I error probability (alpha) was one-sided 0.025, allocated as 0.01 and 0.015 for ITT and poor prognosis final analyses, respectively, with 85% power. Hypothesized HR for ITT was 0.75 at 547 events. Hypothesized HR for poor prognosis was 0.69 assuming 299 events.


635 men were randomized: median age 68 yrs, Karnofsky score ≤80% in 50%. Demographics and exposure to Cbz/P were similar for both arms. In ITT population (n = 635), median OS was 14.2 mo on Cbz/P/C and 13.4 mo on Cbz/P (two-sided p = 0.529; HR 0.946, 95% CI 0.796–1.124). 62% of pts (n = 392) met criteria for poor prognosis; OS was 11.1 mo on Cbz/P/C (n = 195) and 10.9 mo on Cbz/P (n = 197) in this subset (p = 0.470; HR 0.918, 95% CI 0.727–1.158). 28.9% of pts on Cbz/P/C and 25% on Cbz/P discontinued due to progressive disease, and 21.9% and 18.9% due to adverse events (AEs). Arms were comparable in ≥Grade 3 AEs (75.9% vs 66.3%) and SAEs (49.2% vs 42.3%). The most frequently reported ≥Gr3 AEs were neutropenia, anemia, fatigue, asthenia, bone pain, and febrile neutropenia.


In this phase 3 study, no survival benefit was seen in pts receiving Cbz/P/C compared to Cbz/P in both ITT population and poor prognosis subset.

Clinical trial identification


Legal entity responsible for the study

OncoGenex Pharmaceuticals, Inc.


OncoGenex Pharmaceuticals, Inc.


K. Fizazi: The author declares participation on advisory boards and honoraria from Orion, Bayer, Sanofi, Amgen, Genentech, Janssen, Astellas, and Takeda. F. Saad: Grants from OncoGenex during the conduct of the study; grants and personal fees from Sanofi, grants and personal fees from Astellas, grants and personal fees from Janssen, grants and personal fees from Amgen outside the submitted work. A. Flechon: Honoraria: Astellas, Janssen-Cilag, Sanofi, Ipsen Travel: Astellas, Janssen, Sanofi, MSD, Pfizer, Novartis, Bayer, Astra Zeneca. F. Joly: Outside the submitted work: Grant received: Astellas Board, scientific expertise, and congress: Roche, Novartis Board, scientific expertise: Sanofi, Astra Zeneca Congress: Amgen. P. Stewart: OncoGenex: Employee, stock ownership. C. Jacobs: OncoGenex: Employee, executive leadership, stock ownership. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings